Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Carcinoid tumors can be a cause for right heart valve disease, also known as Hedinger syndrome or carcinoid heart disease. Proper understanding of the pathophysiology is of the uttermost importance for adequate treatment of these patients, especially during heart surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713642 | PMC |
| http://dx.doi.org/10.21470/1678-9741-2020-0656 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.
Front Endocrinol (Lausanne)
July 2025
Advanced Theranostics Center for Radiomolecular Precision Oncology, CURANOSTICUM Wiesbaden-Frankfurt, HELIOS DKD Klinik, Wiesbaden, Germany.
Introduction: Patients with pancreatic neuroendocrine neoplasms (P-NEN) may benefit from peptide receptor radionuclide therapy (PRRT). Prediction of overall survival (OS) using statistical models has the potential to guide treatment decisions. In this study, we have generated a clinicopathological and imaging parameter-based internally validated nomogram of patients who received PRRT for metastatic P-NEN to facilitate treatment decision support for the clinical management of such patients.
View Article and Find Full Text PDFCarcinoid Heart Disease: A Rare Complication of Metastatic Neuroendocrine Tumor.
Cureus
January 2025
Cardiology, Henry Ford Health, Grand Blanc, USA.
Carcinoid heart disease (CHD), also known as Hedinger syndrome, is a rare but significant cardiac complication associated with metastatic neuroendocrine tumors (NETs). These tumors secret bioactive substances such as serotonin, leading to fibrotic changes primarily affecting the right-sided heart valves. A case study involving a 69-year-old male presented with a four-month history of diarrhea and a new systolic heart murmur.
View Article and Find Full Text PDFNET-Induced Carcinoid Heart Disease Affecting Both Tricuspid and Aortic Valves Due to Patent Foramen Ovale and Right/Left Shunt: A Multi-imaging Challenge to Nuclear Medicine.
Clin Nucl Med
February 2024
Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Hospital Essen.
Article Synopsis
- * A 53-year-old man with an ileum neuroendocrine tumor and liver metastases developed Hedinger syndrome, experiencing worsening shortness of breath and severe low oxygen levels because of a patent foramen ovale.
- * Diagnostic imaging, including 99mTc-MAA lung perfusion scintigraphy and 68Ga-FAPI-46 PET/CT, helped identify the right-left blood shunting and the characteristic thickening of heart valves linked to serotonin's effects on fibro
Hedinger Syndrome-Lessons Learnt: A Single-Center Experience.
J Cardiovasc Dev Dis
October 2023
Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Centre, 45147 Essen, Germany.
Background: Hedinger syndrome (HS) or carcinoid heart disease (CD) is a rare and challenging manifestation of malignant neuroendocrine tumours (NETs) involving the heart. We aimed to report our experience with surgical strategies and midterm results in HS patients.
Methods: Eleven patients (58 ± 11 (range 41 to 79 years); 5 females) with HS who underwent cardiac surgery in our department between 07/2005 and 05/2023 were analysed.
Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort.
BMC Cancer
April 2023
Department of Medical Oncology and Hematology, University Hospital Zurich and University Zurich, Rämistrasse 100, Zurich, CH-8091, Switzerland.
Background: Carcinoid heart disease is a rare disease which develops in patients with functional neuroendocrine tumors in an advanced tumor state. Patients diagnosed with carcinoid heart disease have a poor longtime prognosis with respect to morbidity and mortality and long-term data on patient outcomes are lacking.
Methods And Results: In this retrospective study, we analyzed outcomes of 23 patients with carcinoid heart disease enrolled into the SwissNet database.